Trials / Withdrawn
WithdrawnNCT04894682
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Lung Cancer or Indeterminate Pulmonary Nodule--A Real World Study
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Guangdong Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to assess the inoculation-related symptoms and long-term effects of COVID-19 vaccines in patients with lung cancer or pulmonary nodules in a real-world setting. The investigators aim to provide high-quality evidence for the COVID-19 vaccines in cancer/pre-cancer patients, and to address their concern about the safety profile of the newly developed vaccines.
Detailed description
This study will enroll lung cancer/pulmonary nodule patients or healthy people who had undergone standard vaccination procedures against SARS-CoV-2/COVID-19. This observatory study will apply an electronic questionnaire to collect general information and post-vaccination symptoms or adverse events of vaccinated pulmonary nodules/lung cancer patients and healthy control. The researchers will further analyze whether the vaccine will promote the progression of primary tumors/pulmonary nodules through long-term follow-up. The investigators aim to assess the adverse events and long-term impact of COVID-19 vaccines in patients with lung cancer or pulmonary nodules in a real-world setting, to provide high-quality evidence for the COVID-19 vaccines in cancer/pre-cancer patients, and to address their concern about the safety profile of the newly developed vaccines.
Conditions
- Lung Cancer
- Pulmonary Nodule, Solitary
- Pulmonary Nodule, Multiple
- COVID-19 Pneumonia
- Vaccine Adverse Reaction
- SARS-CoV-2 Acute Respiratory Disease
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Vaccine inoculation against SARS-CoV-2 | Inoculation with any type of approved vaccines according to the standard or recommended dose |
Timeline
- Start date
- 2021-05-04
- Primary completion
- 2021-08-31
- Completion
- 2022-05-31
- First posted
- 2021-05-20
- Last updated
- 2023-03-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04894682. Inclusion in this directory is not an endorsement.